

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
9 February 2006 (09.02.2006)

PCT

(10) International Publication Number
WO 2006/015195 A1

(51) International Patent Classification:

C12Q 1/533 (2006.01) G01N 33/88 (2006.01)
G01N 33/573 (2006.01)

SABOL, Jeffrey, S. [US/US]; 24 Bertran Dr., Bridgewater, New Jersey 8807 (US). AYERS, Stephen [US/US]; 199 Robins Run West, Swedesboro, NJ 08085 (US).

(21) International Application Number:

PCT/US2005/026945

(74) Agents: KRUPEN, Karen, I. et al.; sanofi-aventis, Route 202-206, P. O. Box 6800, Bridgewater, NJ 08807-0800 (US).

(22) International Filing Date: 28 July 2005 (28.07.2005)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/592,501 30 July 2004 (30.07.2004) US

(71) Applicant (for all designated States except US): AVENTIS PHARMACEUTICALS INC. [US/US]; 300 Somerset Corporate Boulevard, Bridgewater, New Jersey 08807-2854 (US).

(72) Inventors; and


(75) Inventors/Applicants (for US only): CAO, Yang [US/US]; 8 Lewis Drive, Bridgewater, NJ 08807 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,

[Continued on next page]

(54) Title: METHODS FOR DETERMINING THE POTENCY, SPECIFICITY, AND TOXICITY OF HEMATOPOIETIC PROSTAGLANDIN D2 SYNTHASE



(57) Abstract: The present invention relates to a novel and useful method for assaying compounds and agents for their ability to decrease or inhibit the activity of hematopoietic prostaglandin D2 synthase (hPGDS). Specifically, the present invention relates to assays for measuring the potency, specificity and toxicity of hPGDS inhibitors.

WO 2006/015195 A1



FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(48) Date of publication of this corrected version:

21 December 2006

Declarations under Rule 4.17:

- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report*

(15) Information about Correction:

see PCT Gazette No. 51/2006 of 21 December 2006

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.